Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters

Janelidze, Shorena; Ventorp, Filip; Erhardt, Sophie; Hansson, Oskar; Minthon, Lennart; Flax, John; Samuelsson, Martin; Träskman‐Bendz, Lil; Brundin, Lena

doi:10.1016/j.psyneuen.2012.09.010

Cited by 59 publications

(48 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A common comorbid diagnosis among other psychiatric diagnoses is MDD, and the association between cytokines and suicidality may be mediated through MDD (12). Of the 18 included studies, 8 (17,19,20,25,29,31,33,34) included suicidal subjects with different primary and comorbid diagnoses. Studies that defined suicidality as a prior or recent suicide attempt were more likely to include a patient population with different primary diagnoses, as were postmortem studies of completed suicides.…”

Section: Discussionmentioning

confidence: 99%

“…One study found significant decreases in CSF levels of MCP-1/CCL-2, MIP-1β/CCL-4, eotaxin/CCL-11, MCP-4/CCL-13, and TARC/ CCL-17 (p , .05 for each) when comparing patients who attempted suicide with healthy control subjects (20). The study also found a nonsignificant decrease for IP-10/CXCL10 (20).…”

Section: Chemokines In Csfmentioning

confidence: 98%

“…Sensitivity analysis was not possible because of the small number of studies. When assessing single studies, regulated on activation, normal T-cell expressed and secreted (RANTES)/CCL-5 (p , .001)(15) and thymus and activation-regulated chemokine (TARC)/CCL-17 (p , .05)(20) were both significantly lower in suicidal patients versus nonsuicidal patients. Results for macrophage inflammatory protein (MIP)-1β/CCL-4, MCP-4/ CCL-13, and interferon-γ-induced protein (IP)-10/C-X-C motif ligand (CXCL)-10 were not significant(20).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients

Parker

Miller

2015

Biological Psychiatry

291

212

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Chemokines In Csfmentioning

confidence: 98%

mentioning

confidence: 99%

See 1 more Smart Citation

Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients

Parker

Miller

2015

Biological Psychiatry

291

212

View full text Add to dashboard Cite

“…It seems possible that only a portion of the potentially available data is ultimately published in this field. In biomarker research in psychiatry, the use of multiplex or high-throughput technologies at a relatively low cost have allowed the widespread measurement of a range of biomarkers in a single study [43,44]. Therefore, at least in some circumstances, some promising biomarker results may reflect false positives due to multiple statistical testing across studies [45].…”

Section: Discussionmentioning

confidence: 99%

Bias in Peripheral Depression Biomarkers

Carvalho

Köhler

Brunoni

et al. 2016

Psychother Psychosom

View full text Add to dashboard Cite

Background: To aid in the differentiation of individuals with major depressive disorder (MDD) from healthy controls, numerous peripheral biomarkers have been proposed. To date, no comprehensive evaluation of the existence of bias favoring the publication of significant results or inflating effect sizes has been conducted. Methods: Here, we performed a comprehensive review of meta-analyses of peripheral nongenetic biomarkers that could discriminate individuals with MDD from nondepressed controls. PubMed/MEDLINE, EMBASE, and PsycINFO databases were searched through April 10, 2015. Results: From 15 references, we obtained 31 eligible meta-analyses evaluating biomarkers in MDD (21,201 cases and 78,363 controls). Twenty meta-analyses reported statistically significant effect size estimates. Heterogeneity was high (I² ≥50%) in 29 meta-analyses. We plausibly assumed that the true effect size for a meta-analysis would equal the one of its largest study. A significant summary effect size estimate was observed for 20 biomarkers. We observed an excess of statistically significant studies in 21 meta-analyses. The summary effect size of the meta-analysis was higher than the effect of its largest study in 25 meta-analyses, while 11 meta-analyses had evidence of small-study effects. Conclusions: Our findings suggest that there is an excess of studies with statistically significant results in the literature of peripheral biomarkers for MDD. The selective publication of ‘positive studies' and the selective reporting of outcomes are possible mechanisms. Effect size estimates of meta-analyses may be inflated in this literature.

show abstract

“…Although the enzyme-linked immunosorbent assay (ELISA) technique has been widely used to measure serum cytokine levels in clinical studies, the recent development of multiplex immunoassays now offers the possibility of simultaneously measuring the levels of expression of large panels of proteins using a small volume of sample and at an affordable price (Altara et al, 2015;Butler et al, 2015;Guest et al, 2011;Halaris et al, 2015;Ho et al, 2015;Janelidze et al, 2013;Nielsen et al, 2015;Schwarz et al, 2012). Nevertheless, it is important for the new and constantly upgraded multiplex technologies to prove that their performance is at least equal to the 'gold standard' ELISA for each analyte tested in the combinations (Bastarache et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays

Belzeaux

Lefebvre

Lazzari

et al. 2017

Psychoneuroendocrinology

View full text Add to dashboard Cite

Cytokines produced by both immune and non-immune cells are likely to play roles in the development and/or progression of psychiatric disorders. Indeed, many investigators have compared the blood cytokine levels in psychiatric patients with those of healthy controls or monitored their levels in patients during disease progression to identify biomarkers. Nevertheless, very few studies have confirmed that such cytokines remain stable in healthy individuals through periods of weeks and months. This is an important issue to consider before using blood cytokine levels as biomarkers of disease traits, disease state, or treatment response. Although multiplex assay technology represents an advance in identifying biomarkers because it allows simultaneous examination of large panels of analytes from a small volume of sample, it is necessary to verify whether these assays yield enough sensitivity and reproducibility when applied to the blood from neuropsychiatric patients. Therefore, we compared two multiplex immunoassays, the bead-based Luminex® (Bio-Rad) and the electro-chemiluminescence-based V-plex® (MesoScaleDiscovery), for the detection and quantification of 31 cytokines, chemokines and growth factors in both the sera and plasma of patients with major depressive episodes (MDE) and age-and sex-matched healthy control subjects during a 30-week period. Although both platforms exhibited low coefficients of variability (CV) between the duplicates in the calibration curves, the linearity was better in general for the V-PLEX® platform. However, neither platform was able to detect the absolute values for all of the tested analytes. Among the 16 analytes that were detected by both assays, the intra-assay reproducibility was in general better with the V-PLEX® platform. Although it is not a general rule that the results from sera and plasma will be correlated, consistent results were more frequent with the V-PLEX® platform. Furthermore, the V-PLEX® results were more consistent with the gold standard ELISA simplex assay for IL-6 in both sera and plasma. The intra-individual variability of the measurements, among the sera and plasma for the 4 samples harvested from each healthy individual, was low for Eotaxin, G-CSF, IL-4, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β and VEGF, but intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, these data suggest that extreme caution is needed in translating the results of multiplex cytokine profiling into biomarker discovery in psychiatry. Dear Editor,We thank you and the Editor in chief, Robert Dantzer, for reaching the conclusion to ultimately publish our manuscript. Following your suggestion, we changed the tiltle to: "How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays".We were concerned by the persistent negative comments of Reviewer#3, stressing out that our comparison between the two platforms we have worked with suffers a number of theoretical and technical limitations because...

show abstract

Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters

Cited by 59 publications

References 51 publications

Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients

Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients

Bias in Peripheral Depression Biomarkers

How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays

Contact Info

Product

Resources

About